Redeye returns with an update following AlzeCure's Q2 earnings release, which aligned with our expec...
Redeye is positive to GomSpace’s Q2 report published this morning, where the company slightly exceed...
With additional funds and a streamlined organisation, Sprint Bioscience continues to proactively pro...
Redeye notes that Smart Eye’s Q2 reflected underlying solid performance, with Smart Eye reaching a k...
* Orders -10%, sales +3%, adj. EBITA -6% vs. ABGSCe * Enedo drove EBITA miss, Inission beat; Enedo b...
Redeye updates on Gentoo Media after weaker-than-expected Q2 results and lowered full-year 2025 guid...
Solwers' Q2 sales were largely in line with our expectations, but profitability was clearly below, s...
* Scale and presence underpin growth and margin expansion * Sharper execution on cross-segment syner...
* Q2 beat with activity picking up * Pre-tax profit up by 13-16% for 2026-27e * 2025e-27e EV/EBIT of...
Nettoomsättningen för det andra kvartalet 2025 uppgick till 142,1 MSEK (114,2), motsvarande en organ...
* '25e-'27e sales cut by 6-1% * Market softness persists, delaying customer decisions * Cost-cutting...
Redeye comments on Lipigon’s Q2 report. At the end of June, the company recruited the last patient t...
* Comps to become easier in '26e * Cutting '25e-'27e adj.
Redeye provides an initial take following the release of Corline’s Q2 2025 report.
Redeye comments on Gentoo Media’s Q2-results which were lower than expected and the company has trim...
* Q2 EBIT SEK -74m (vs. ABGSCe 103m) * EBIT negatively impacted by delay in Pome project timeline * ...
Redeye views last Friday’s large block transaction in Physitrack shares as a clear positive for the ...
Acuvi redovisade ökad nettoomsättning och EBIT i det andra kvartalet.
Redeye comments on Episurf’s rights issue of Units, which was oversubscribed to approximately 162.
We hosted NoHo Partners' CEO Jarno Suominen for a lunch meeting today in Helsinki.
